CTT 1401

Drug Profile

CTT 1401

Alternative Names: 177Lutetium CTT1401; [177Lu]CTT1401; CTT1401

Latest Information Update: 01 Aug 2016

Price : $50

At a glance

  • Originator Cancer Targeted Technology
  • Class Radiopharmaceuticals
  • Mechanism of Action DNA modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Prostate cancer

Most Recent Events

No Data Available
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top